A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

被引：6
作者：
Kwon, Daniel Hyuck-Min [1 ,2 ]
Friedlander, Terence [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
ABIRATERONE; THERAPY;
D O I：
10.21037/atm.2019.09.21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 13 - 24
  • [2] The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy
    Barata, Pedro
    Swami, Umang
    Agarwal, Neeraj
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (03) : 147 - 150
  • [3] Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer
    Fukuokaya, Wataru
    Mori, Keiichiro
    Yanagisawa, Takafumi
    Urabe, Fumihiko
    Rajwa, Pawel
    Briganti, Alberto
    Shariat, Shahrokh F.
    Matsubara, Nobuaki
    Kimura, Takahiro
    Hirakawa, Akihiro
    CANCER, 2025, 131 (07)
  • [4] The evolving options in metastatic castration-sensitive prostate cancer
    Hamilou, Zineb
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2020, 14 (03) : 270 - 275
  • [5] Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or ...
    Barata, Pedro C.
    Sartor, A. Oliver
    CANCER, 2019, 125 (11) : 1777 - 1788
  • [6] Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina, Carlo
    Messina, Marco
    Boccardo, Francesco
    EUROPEAN UROLOGY, 2018, 73 (01) : 147 - 148
  • [7] Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer
    Yang, Yun-Jie
    Kong, Yun-Yi
    Li, Gao-Xiang
    Wang, Yue
    Ye, Ding-Wei
    Dai, Bo
    BJU INTERNATIONAL, 2019, 124 (02) : 258 - 267
  • [8] Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    ANTICANCER RESEARCH, 2019, 39 (03) : 1391 - 1396
  • [9] Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide
    Lowentritt, Benjamin
    Pilon, Dominic
    Khilfeh, Ibrahim
    Rossi, Carmine
    Muser, Erik
    Kinkead, Frederic
    Waters, Dexter
    Ellis, Lorie
    Lefebvre, Patrick
    Brown, Gordon
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 253.e1 - 253.e9
  • [10] Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer
    Struss, Werner J.
    Black, Peter C.
    UROLOGY, 2017, 109 : 1 - 2
12345